News

Virovek, a commercial-stage biotechnology company specializing in the development, manufacturing and sale of custom-made AAV- and lentivirus-based vectors for therapeutic development, today announced that the Company has appointed Peter L. Hoang as its Chief Executive Officer.

September 13, 2023. Virovek is launching an online storefront for premade product sales. Customers will now be able to add premade AAV to their carts with the click of a button, place their orders entirely online, and have their orders shipped to them anywhere in the...

Hayward, California - March 10, 2021 Virovek is pleased to launch a new service line, producing adeno-associated virus (AAV) vector in human embryonic kidney HEK293 cells through three plasmid transfection method. See our HEK293 page for more details and inventory...

Boston, Massachusetts, June 10-11, 2013 — Virovek was invited to present and showcase its large-scale AAV vector manufacturing process at this inaugural bio-manufacturing and processing…

Hayward, California, June 3, 2013 — Virovek announced today it has discontinued its baculovirus titration kit, BacEZ Titer Kit, but will still provide technical support to customers who have previously purchased this product.

Nanjing, China, April 25-27, 2013 — Company CEO, Dr. Haifeng Chen, chaired the Gene Therapy session and presented Virovek’s latest suicide gene therapy technology using toxins to target cancer cells at the BIT’s 4th Annual World DNA and Genome Day...

San Francisco, California, January 7-9, 2013 — Virovek presented its newest patented technology to manufacture AAV vectors harboring toxins, the first of its kind, at the Biotech Showcase 2013 where private and small- and mid-cap…

San Francisco, California, and Houston, TX, May 16, 2012 — Avalanche Biotechnologies, Inc. and Lonza announced their major global manufacturing collaboration to use Virovek’s patented technologyto produce AAV vectors for gene therapy studies.

Hayward, California, June 10, 2011 — Virovek announced that a new book “Methods in Molecular Biology 737 — Viral Vector for Gene Therapy” has been published by Humana Press (Editors: Otto-Wilhelm Merten & Mohamed Al-Rubeai), in which Dr. Haifeng Chen…

Hayward, California, November 20, 2009 — Virovek announced today that starting on January 1, 2010, Virovek will provide up to 50% discount in fees of AAV vector production services for academic and non-profit organizations…

Hayward, California, April 10, 2009 — Virovek announced today that it launched a new product, BacEZ Titer Kit, for baculovirus titration. This kit offers customer more reagents for lower cost as compared with other competitors’ similar product. It uses a standard...

San Diego, California, January 12, 2009 — Company CEO, Dr. Haifeng Chen, gave a presentation today at the PepTalk 2009 Conference (January 11 – 16, 2009, San Diego, CA) entitled “The Artificial Intron: A New Tool to express Overlapping Genes in Insect Cells…

Hayward, California, January 7, 2009 — Virovek announced that it signed a licensing agreement with Massachusetts Institute of Technology (MIT) in which MIT will use Virovek’s AAV production technology for its neuroscience research in the viral core facility newly...

Hayward, California, February 6, 2008 — Virovek announced today that its manuscript entitled “Intron splicing-mediated expression of AAV Rep and Cap genes and production of AAV vectors in insect cells” has been…

Hayward, California, October 4, 2007 — Virovek launched a free AAV vector production program today to serve the biotechnology and biopharmaceutical research communities. Because of its robustness of the novel AAV production technology, Virovek is able to cut cost on...